Vuno has secured a strategic investment of 10 billion KRW in the 'Compas Pathway NXVP New Technology Investment Fund No. 1', led by Pathway Investment, through perpetual convertible bonds to support its global expansion and operational expenses, with a conversion price set at 20,095 KRW.

Information on the target

Vuno, a leading medical artificial intelligence (AI) company, has confirmed its strategic investment participation in the 'Compas Pathway NXVP New Technology Investment Fund No. 1', led by Pathway Investment, amounting to 10 billion KRW. This funding will be executed in the form of perpetual convertible bonds and will be utilized for operational expenses, including Vuno's global business expansion. The conversion price is set at 20,095 KRW.

Vuno is actively preparing for international market entry, focusing on its flagship product, the AI-based cardiac arrest prediction medical device, VUNO Med®-DeepCARS®. The company recently hosted a symposium inviting global experts in critical care medicine to discuss AI and patient safety, further solidifying its leadership in the industry.

Industry overview in the target’s specific country

The South Korean healthcare industry is undergoing a significant transformation, driven by advancements in technology and an increasing demand for innovative medical solutions. The integration of artificial intelligence in healthcare is particularly noteworthy, as